MORGAN STANLEY PLC/CALL/ELI LILLY & CO/370/0.01/21.03.25 | Market Closed - Börse Stuttgart 20:26:28 28/06/2024 BST | ||
| 5.2 EUR | +0.97% |
|
| Current month | +21.50% | ||
| 1 month | +22.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 5.2 | +0.97% |
| 27/06/24 | 5.15 | +0.19% |
| 26/06/24 | 5.14 | -0.39% |
| 25/06/24 | 5.16 | +1.38% |
| 24/06/24 | 5.09 | +1.80% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 08:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MB54AD |
| ISIN | DE000MB54AD9 |
| Date issued | 31/03/2023 |
| Strike | 370 $ |
| Maturity | 21/03/2025 (265 Days) |
| Parity | 100 : 1 |
| Emission price | 0.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.24 € |
|---|---|
| Lowest since issue | 0.53 € |
| Spread | 0.01 € |
| Spread % | 0.19% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
